Results 21 to 30 of about 3,371 (214)
The dopamine D3-preferring D2/D3 dopamine receptor partial agonist, cariprazine, reverses behavioral changes in a rat neurodevelopmental model for schizophrenia [PDF]
, 2016 Current antipsychotic medication is largely ineffective against the negative and cognitive symptoms of schizophrenia. One promising therapeutic development is to design new molecules that balance actions on dopamine D2 and D3 receptors to maximise ...Adham, Nika, Fone, Kevin C.F., Gyertyán, Istvan, King, Madeleine V., Kiss, Béla, Watson, David J.G. +5 morecore +1 more sourceLong-term safety and tolerability of cariprazine as adjunctivetherapy in major depressive disorder [PDF]
, 2021 Lack of treatment response is a critical problem in major depressive disorder (MDD). Cariprazine is a D3-preferring dopamine D3/D2 receptor partial agonist and 5-HT1A partial agonist.Barabássy, Ágota, Burgess, Maria V., Chen, Changzheng, Durgam, Suresh, Earley, Willie R., Németh, György, Vieta i Pascual, Eduard, 1963-, Zhong, Yan +7 morecore +1 more sourceThe role of kinetic context in apparent biased
agonism at GPCRs [PDF]
, 2016 Biased agonism describes the ability of ligands to stabilize different conformations of a GPCR linked to distinct functional outcomes and offers the prospect of designing pathway-specific drugs that avoid on-target side effects. This mechanism is usually A Akinc, A Hill, A Lahti, A Saulière, AW Kahsai, B Masri, C Sampaio, D Guo, D Möller, D Sykes, D Unett, D Wacker, DA Sykes, DR Sibley, EJ Whalen, ET van der Westhuizen, F Pedregosa, GJ Kilpatrick, H Abdi, H Motulsky, H Sheth, J Allen, J McPherson, J Shonberg, J Shonberg, JD Urban, JD Urban, JD Violin, JE Murphy, JJ Liu, JP Overington, JP Vilardaga, JR Lane, JW Black, JW Wisler, KV Andreassen, L Carboni, L Gazi, M Griffin, M Szabo, M Vilums, MT Drake, N Tschammer, O Agid, P Molinari, P Tummino, R Irannejad, R Rahmeh, S Ahn, S Durgam, S Ferrandon, S Galandrin, S Nijmeijer, S Rajagopal, SJ Charlton, SK Shenoy, T Kenakin, T Kenakin, T Kenakin, T Warne, W Stallaert, X-T Chen, Y Cheng +62 morecore +1 more sourceMonoaminergic and histaminergic strategies and treatments in brain diseases [PDF]
, 2016 The monoaminergic systems are the target of several drugs for the treatment of mood, motor and cognitive disorders as well as neurological conditions.Adell, Ahles, Ahmed, Airas, Aletrino, Alper, Andersson, Anna Stasiak, Arai, Arrang, Artigas, Artigas, Artigas, Artigas, Ashby, Ban, Bar-Am, Barak, Barak, Barnes, Bastide, Bauer, Bautista-Aguilera, Beaulieu, Bel, Benarroch, Berman, Bett, Bezard, Bezard, Bezard, Bhide, Bialer, Binda, Blier, Blier, Boomsma, Braak, Bronstein, Brown, Buckley, Bunney, Burke, Butini, Bézard, Carboni, Cardamone, Carlsson, Carruba, Carta, Chang, Cipriani, Cirrito, Citrome, Citrome, Claeysen, Clineschmidt, Combarros, Conklin, Cooper, Cotzias, Cotzias, Coulter, Cremers, Cremers, Cryan, Cryan, Curet, Dale, Davidson, Daws, De Deurwaerdère, De Deurwaerdère, De Deurwaerdère, De Deurwaerdère, De Deurwaerdère, de la Fuente-Fernández, de la Fuente-Fernández, del Mar Hernandez, Del Tredici, Delaville, Delaville, Delgado, Deroche-Gamonet, Deutch, Devinsky, Devroye, Di Chiara, Di Chiara, Di Chiara, Di Giovanni, Di Giovanni, Dias, DiNapoli, Dorotea Mück-Šeler, Dubravka Svob Strac, Durif, Ebadi, Eisenhofer, Elrod, Emilien, Esbenshade, Fakhfouri, Fakhfouri, Fangmann, Ferrer, Fidalgo, Filip, Finberg, Fisher, Fitoussi, Fitzgerald, Fletcher, Fornito, Fowler, Fox, Friedman, Gagnon, Galati, Garattini, Garcia-Alloza, Garcia-Alloza, Gardier, Gbahou, Geldenhuys, Ghanemi, Giuseppe Di Giovanni, Grammas, Greendyke, Grudzien, Guglielmotto, Guiard, Guidi, Gumnick, Gururajan, Gustafson, Haefely, Hale, Hamon, Han, Harden, Haslam, Hauser, Hawirko, Heneka, Heneka, Hensler, Hernandez-Guillamon, Hernandez-Guillamon, Higgins, Himeno, Hiranita, Holm, Howell, Hoyer, Iadecola, Iadecola, Iderberg, Ilse J. Smolders, Invernizzi, Invernizzi, Irene Bolea, Ittner, Iversen, Jackson, Jacquot, Jalkanen, James, Jellinger, Jenner, Jobe, Joyce, Kalaria, Kalinin, Kapur, Kapur, Karran, Kasper, Keith F. Tipton, Kepe, Kiloh, Kiss, Koch, Koob, Koob, Koob, Koob, Kroeze, Kuczenski, Kumar, Kurkijärvi, Lai, Lai, Lanari, Laura Della Corte, Le Moal, Lecklin, Lees, Leggio, Leiser, León, Li, Liu, Liu, Liu, Lopez, Lorke, Lucas, Lucas, Luque, Luscombe, López-Muñoz, López-Muñoz, Marchesi, Markham, Marner, Martorana, Martorana, Masaki, Matea Nikolac Perkovic, Mateo, Mauri, Mazzucchi, McCann, McCreary, McDonald, Melamed, Meltzer, Meltzer, Meltzer, Meltzer, Meltzer, Meltzer, Meltzer, Meltzer, Meltzer, Mendez-David, Meneses, Mercedes Unzeta, Miguelez, Miguelez, Millan, Millan, Millan, Millan, Millan, Millan, Millan, Millan, Montse Sole, Morisset, Muck-Seler, Murphy, Mustapic, Myöhänen, Nakazato, Navailles, Navailles, Navailles, Navailles, Navailles, Navailles, Navailles, Nela Pivac, Olanow, Owen, Page, Palmieri, Panula, Parsons, Pascual, Payton, Perez-Caballero, Perez-Lloret, Peskind, Philippe De Deurwaerdère, Piñeyro, Porras, Poyurovsky, Preda, Provensi, Provensi, Racagni, Ramirez, Ramsay, Rantamaki, Rascol, Ratliff, Reifler, Remington, Reynolds, Rezvani, Richtand, Riederer, Ries, Rommelfanger, Rosenzweig-Lipson, Roth, Sachdev, Sagud, San, Sanchez, Sanz, Sanz, Saura, Saura, Scheen, Schendzielorz, Schreiber, Seeman, Seeman, Seeman, Shankle, Shen, Simoni, Sims, Smith, Solé, Solé, Stahl, Stansley, Stansley, Storga, Strac, Sun, Svenningsson, Szot, Tammimäki, Tanaka, Taylor, Terry, Thase, Thomas, Tighilet, Tohgi, Tonelli, Torres, Trillo, Tronci, Udenfriend, Versijpt, Vickers, Visanji, Vivero, Voigt, Werner, Wieslawa A. Fogel, Wimalasena, Wong, Yan, Youdim, Yu, Zeller, Zlokovic, Zohar, Šimić +355 morecore +3 more sourcesThe Efficacy of Pharmacological Interventions in the Treatment of Major Depressive Disorder and Bipolar Depression With Mixed Features: A Systematic Review. [PDF]
Bipolar DisordABSTRACT Background
There is a need to provide up‐to‐date, clinically translatable data as it relates to the treatment of a major depressive episode (MDE) with mixed features. Methods
PubMed and OVID were searched from inception to July 22, 2024. Randomized controlled trials (RCTs) investigating the efficacy of pharmacological agents for adults with ...Xiao N, Yin L, Lee S, Teopiz KM, Wong S, Le GH, Badulescu S, Lo HKY, Vinberg M, Cao B, Grande I, Rosenblat JD, McIntyre RS. +12 moreeuropepmc +2 more sourcesPreferential Effects of Cariprazine on Counteracting the Disruption of Social Interaction and Decrease in Extracellular Dopamine Levels Induced by the Dopamine D3 Receptor Agonist, PD-128907 in Rats: Implications for the Treatment of Negative and Depressive Symptoms of Psychiatric Disorders
Frontiers in Psychiatry, 2022 The negative and cognitive symptoms of schizophrenia and related disorders may be due to reduced dopaminergic tone in cortical brain areas. Alteration in the function of dopamine (DA) D3 receptors may play a role in this cortical hypofunctionality and ...Jan Kehr, Jan Kehr, Fu-Hua Wang, Fumio Ichinose, Shimako Yoshitake, Shimako Yoshitake, Bence Farkas, Béla Kiss, Nika Adham +8 moredoaj +1 more sourceDopamine D3 Receptors Inhibit Hippocampal Gamma Oscillations by Disturbing CA3
Pyramidal Cell Firing Synchrony [PDF]
, 2016 Cortical gamma oscillations are associated with cognitive processes and are
altered in several neuropsychiatric conditions such as schizophrenia and
Alzheimer’s disease.Adham, Andersson, Axmacher, Bender, Bouthenet, Buehlmann, Cools, Fisahn, Fisahn, Girgis, Glickstein, Grace, Gross, Gulyás, Gurevich, Hamidovic, Hájos, Jönsson, Khan, Kiss, Klaft, Kwon, Laszy, Lee, Light, Lisman, Loiseau, MacDonald, Millan, Missale, Miyamoto, Mulert, Nakajima, Parikh, Powell, Richtand, Rolls, Rubin, Schiller, Schulz, Schulz, Smith, Swant, Szekeres, Tadori, Talkowski, Uhlhaas, Ukai, Watson, Womelsdorf, Xing, Çalişkan +51 morecore +2 more sourcesTolerability of cariprazine in the early stage of schizophrenia: A pooled, post-hoc analysis of 4 phase ii/iii double-blind placebo-controlled trials
European Psychiatry, 2021
Introduction
In the early stage of schizophrenia (first 5 years), the most important clinical target besides symptom control is relapse prevention as each relapse significantly decreases the possibility of preferable long-term outcomes.Z.B. Dombi, K. Acsai, Á. Barabássy, B. Sebe, I. Laszlovszky, G. Vass, B. Szatmári, M. Patel, W. Earley, G. Németh +9 moredoaj +1 more sourceFactors modifying drug and placebo responses in randomized trials for bipolar mania [PDF]
, 2014 Factors modifying drug and placebo responses in randomized trials for bipolar mania. Yildiz A, Vieta E, Tohen M, Baldessarini RJ. Source Department of Psychiatry, Dokuz Eylül University, Izmir, Turkey.Baldessarini, Ross J., Tohen, Mauricio, Vieta i Pascual, Eduard, 1963-, Yildiz, Aysegül +3 morecore +2 more sources
